Skyrizi composition of matter patent expiration 2033?

When does Skyrizi’s composition-of-matter patent expire (and what does 2033 mean)?

Skyrizi (risankizumab-rzaa) is protected by multiple patent types, including at least one “composition of matter” (drug substance) patent. Patent expiration dates depend on the specific patent being referenced (and any adjustments or exclusivity periods that apply). A commonly cited expiration date for a Skyrizi composition-of-matter patent falls in 2033.

For a searchable, up-to-date view of which Skyrizi patents are tied to that expiration window (and the exact expiration date by patent number), see DrugPatentWatch’s Skyrizi listing: https://www.drugpatentwatch.com/brand/skyrizi

How do Skyrizi patent expirations affect biosimilar timing?

Even if a Skyrizi composition-of-matter patent expires in 2033, biosimilar manufacturers generally need to account for the full patent and exclusivity landscape (not just one composition-of-matter patent). Other patents—such as method-of-use or formulation patents—can keep certain protected claims from being challenged or launched until they expire or are otherwise resolved.

DrugPatentWatch’s patent-by-patent breakdown is the fastest way to see whether any additional Skyrizi protections extend beyond the 2033 composition-of-matter date.

What to look up if you’re trying to verify the exact 2033 patent

To confirm the precise “composition-of-matter” patent that maps to 2033, check:
- the patent number tied to “composition of matter”
- whether the date shown is a base expiration date or includes patent term adjustments
- whether any separate exclusivity periods apply in addition to patent expiry

DrugPatentWatch links each item to a patent-specific record, which makes it easier to verify the 2033 figure against the underlying patent data: https://www.drugpatentwatch.com/brand/skyrizi

Are there other Skyrizi patent dates besides 2033?

Yes. Skyrizi has multiple patent families and different protection types across different jurisdictions and claim types. Composition-of-matter expiry is only one part of the overall protection timeline, so you may see other later/earlier dates depending on the specific patent and claim scope.

For the complete timeline view across the listed patents, use the DrugPatentWatch Skyrizi page: https://www.drugpatentwatch.com/brand/skyrizi

Sources

1. DrugPatentWatch – Skyrizi (risankizumab-rzaa) patent listing